Vimta Labs Limited
VIMTALABS · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹516.93.
Piotroski F-score 7/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%18.6%
- ✓Low debt (D/E < 0.5)0.01x
- ✓Positive free cash flow
- ✓Revenue growth > 10%17%
- ✓Earnings growing14%
- ✓Net margin ≥ 10%18.9%
- ✓Current ratio > 1.53.43
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✕Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 14.92
- ✓Piotroski ≥ 77/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (18.6%).
- •Lightly leveraged balance sheet.
- •Healthy profit margin (18.9%).
- •Financially solid — Altman Z 14.92.
- •High Piotroski quality score (7/9).
Weaknesses
- •Price below its 200-day moving average (downtrend).
Opportunities
- •Revenue growing (17% YoY).
- •Trading in our value buy zone versus sector peers.
- •Well off its 52-week high — possible mean-reversion.
- •Trades ~20% below our estimated fair value.
About Vimta Labs Limited
Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract research and testing for agrochemical and specialty chemical companies. It also provides
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.